Skip to content
PubMed This is a summary of 113 peer-reviewed journal articles Updated
Surgery

Exocrine Pancreatic Carcinoma: A Patient Guide

At a Glance

Treatment for exocrine pancreatic cancer is individualized: imaging shows whether the tumor can be removed safely, while spread, overall health, and tumor biology guide the plan. Multidisciplinary care also addresses genetic testing, nutrition, enzyme replacement, and symptoms.

Exocrine pancreatic carcinoma is a complex disease that begins in the cells responsible for producing the enzymes that help your body digest food. The most common form, Pancreatic Ductal Adenocarcinoma (PDAC)—which this guide primarily focuses on—is known for its aggressive nature and its tendency to develop a dense, protective environment around the tumor [1]. A rarer subtype, Pancreatic Acinar Cell Carcinoma (PACC), behaves somewhat differently and requires specialized advice. Because the pancreas is located deep in the abdomen, symptoms are often subtle or easily confused with common digestive issues, which means the disease is frequently diagnosed at a stage where it requires a highly coordinated, intensive approach to treatment [2].

Navigating this diagnosis requires a multidisciplinary care team—a group of specialists including surgeons, medical oncologists, gastroenterologists, and dietitians who work together to create a unified plan [3]. Your treatment path is not determined by a single factor, but by a combination of things including how the tumor relates to the major blood vessels surrounding the pancreas. This “resectability” status is a major factor that helps determine whether your care begins with surgery to remove the tumor or with chemotherapy to shrink the disease and protect the rest of your body [4]. Other factors like distant metastasis, your overall fitness, and tumor biology are equally important. Alongside this physical mapping, high-quality pathology and genetic testing are essential to identify the specific molecular “engine” driving the cancer, which can sometimes reveal targeted therapies or clinical trials tailored to your unique biology [5].

Beyond the cancer itself, managing the daily impact on your body is a critical pillar of your care. Because the tumor often interferes with the organ’s natural functions, many people experience Exocrine Pancreatic Insufficiency (EPI), which can cause significant weight loss and malnutrition [6]. Proactively addressing these symptoms with Pancreatic Enzyme Replacement Therapy (PERT) and integrated supportive care is not just about comfort; it is about maintaining the physical strength necessary to complete your treatments [7]. While the road ahead is challenging, modern care focuses on treating the whole person, ensuring that your quality of life and symptom management are prioritized alongside the effort to control the disease [8]. (Note: Bracketed codes refer to citations in the medical literature.)

Common questions in this guide

What type of cancer is exocrine pancreatic carcinoma?
Exocrine pancreatic carcinoma is a cancer that starts in the pancreas cells that make digestive enzymes. Pancreatic ductal adenocarcinoma, or PDAC, is the most common form; pancreatic acinar cell carcinoma is rarer and may need specialized advice.
How does the resectability of a pancreatic tumor affect treatment?
Resectability describes whether the tumor can be removed safely, based in large part on its relationship to the major blood vessels near the pancreas. Imaging, spread to distant sites, overall fitness, and tumor biology help the care team decide whether treatment starts with surgery or chemotherapy.
Why are germline and somatic genetic tests used in pancreatic cancer?
Germline testing looks for inherited changes, while somatic testing examines genetic changes in the tumor itself. Results can sometimes identify a targeted treatment or a clinical trial suited to the cancer's biology.
What is pancreatic enzyme replacement therapy, and why might I need it?
Exocrine pancreatic insufficiency occurs when the pancreas does not provide enough digestive enzymes, which can contribute to weight loss and malnutrition. Pancreatic enzyme replacement therapy, along with dietitian and supportive care, can help the body digest food and maintain strength during treatment.
Who may be involved in an exocrine pancreatic cancer care team?
A coordinated team may include a surgeon, medical oncologist, gastroenterologist, dietitian, pathologist, and palliative care specialist. Working together helps align cancer treatment with nutrition, symptom management, and quality-of-life needs.
When should nutrition and palliative care support begin?
Nutrition support and palliative care can be introduced early, alongside cancer-directed treatment, to address symptoms and quality of life. Ask your care team whether a dietitian and palliative care specialist should be involved now.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my case being reviewed by a multidisciplinary tumor board to ensure all specialists agree on the plan?
  2. 2.Based on my imaging, what is the 'resectability' status of my tumor, and how does that affect the sequence of my care?
  3. 3.Have we completed both germline and somatic genetic testing to look for targeted treatment options?
  4. 4.Can I meet with a dietitian and a palliative care specialist now to help manage my symptoms from the start?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils.

    Schawkat K, Manning MA, Glickman JN, Mortele KJ

    Radiographics : a review publication of the Radiological Society of North America, Inc 2020; (40(5)):1219-1239 doi:10.1148/rg.2020190184.

    PMID: 32678699
  2. 2

    The connection between innervation and metabolic rearrangements in pancreatic cancer through serine.

    Dong M, Cao L, Cui R, Xie Y

    Frontiers in oncology 2022; (12()):992927 doi:10.3389/fonc.2022.992927.

    PMID: 36582785
  3. 3

    Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

    Tempero MA, Malafa MP, Al-Hawary M, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(8)):1028-1061 doi:10.6004/jnccn.2017.0131.

    PMID: 28784865
  4. 4

    International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.

    Isaji S, Mizuno S, Windsor JA, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018; (18(1)):2-11 doi:10.1016/j.pan.2017.11.011.

    PMID: 29191513
  5. 5

    Pancreatic Cancer: A Review.

    Park W, Chawla A, O'Reilly EM

    JAMA 2021; (326(9)):851-862 doi:10.1001/jama.2021.13027.

    PMID: 34547082
  6. 6

    Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis.

    Iglesia D, Avci B, Kiriukova M, et al.

    United European gastroenterology journal 2020; (8(9)):1115-1125 doi:10.1177/2050640620938987.

    PMID: 32631175
  7. 7

    Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

    Khorana AA, Mangu PB, Berlin J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(21)):2541-56 doi:10.1200/JCO.2016.67.5553.

    PMID: 27247221
  8. 8

    Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer.

    O'Brien J, Halsey B, Connors M, et al.

    Journal of palliative medicine 2025; (28(2)):217-223 doi:10.1089/jpm.2024.0313.

    PMID: 39636708

This guide about exocrine pancreatic carcinoma is for informational purposes only and does not constitute medical advice. Your oncology team should interpret your imaging, pathology, genetic testing, and treatment options for your individual situation.

Get notified when new evidence is published on exocrine pancreatic carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.